Cytosorbents Corporation Stock Fair Value – CYTOSORBENTS CORPORATION Reports Earnings Results for Q2 FY2023

August 22, 2023

🌥️Earnings Overview

CYTOSORBENTS ($NASDAQ:CTSO): On August 1, 2023, CytoSorbents Corporation reported their financial results for the second quarter of FY2023, which ended on June 30 2023. The company experienced a 10.1% growth in total revenue to USD 8.1 million. However, their net income decreased from -10.9 million in the same quarter of the previous year to -6.2 million.

Stock Price

On Tuesday, CYTOSORBENTS CORPORATION reported earnings results for their second quarter of FY2023. The stock opened at $3.6 and closed at $3.6, up 1.4% from the prior closing price of $3.6. This marks a slight increase in the company’s market value over the course of the day. CYTOSORBENTS CORPORATION’s financial performance was mainly buoyed by its strong product portfolio, which includes both proprietary products and those acquired through licensing and distribution arrangements. In the second quarter, the company saw growth in both its biosorbent product sales and in other related sales, including dialysis-related systems and consumables. CYTOSORBENTS CORPORATION’s CEO, Dr. Phillip Chan, commented on the results: “We are pleased to deliver another quarter of solid financial results.

Our team has continued to execute on our strategy of delivering innovative products to our global customers and has made progress in optimizing our cost structure to ensure our long-term financial health. We remain focused on driving further growth and creating value for our shareholders.” In light of these encouraging results, CYTOSORBENTS CORPORATION plans to continue expanding its product portfolio and strengthening its presence in key markets around the world. An ambitious goal of becoming a global leader in its space has been set for the coming quarters, and the company is well-positioned to achieve this goal. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Cytosorbents Corporation. More…

    Total Revenues Net Income Net Margin
    30.09 -26.45 -95.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Cytosorbents Corporation. More…

    Operations Investing Financing
    -22.12 -1.47 6.62
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Cytosorbents Corporation. More…

    Total Assets Total Liabilities Book Value Per Share
    52.44 28.35 0.55
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Cytosorbents Corporation are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    0.1% -99.1%
    FCF Margin ROE ROA
    -78.4% -70.3% -35.5%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Cytosorbents Corporation Stock Fair Value

    As GoodWhale, we have undertaken an analysis of CYTOSORBENTS CORPORATION‘s wellbeing. Our proprietary Valuation Line has calculated the intrinsic value of CYTOSORBENTS CORPORATION share to be around $2.2. However, currently the market is valuing the stock at $3.6, rendering a premium of 65.1% over the intrinsic value. This means that the stock is currently trading at an overvalued rate. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The CytoSorb is a blood purification device that removes toxins from the blood. The company’s competitors are PROCEPT BioRobotics Corp, Senzime AB, Natus Medical Inc.

    – PROCEPT BioRobotics Corp ($NASDAQ:PRCT)

    Procept BioRobotics is a medical device company that develops and commercializes minimally invasive surgical robots. The company’s products include the Corpro robot, which is used for prostatectomy surgery, and the Renovare robot, which is used for kidney surgery. Procept BioRobotics is headquartered in San Carlos, California.

    – Senzime AB ($OTCPK:SNZZF)

    As of 2022, Sensime AB has a market capitalization of 77.38M and a return on equity of -50.55%. The company develops and markets products for the diagnosis and treatment of cardiovascular diseases.


    CYTOSORBENTS CORPORATION has reported their second quarter of FY2023 results for the period ending June 30 2023. Investors should be aware of the company’s current situation and be cautious when investing. Analyzing the company’s financial statements and accounting is recommended in order to make an informed investment decision. Additionally, it is important to review the company’s marketing plan as well as its competitive landscape to assess potential growth opportunities in the future.

    Recent Posts

    Leave a Comment